tada-images-shutterstock

16 November 2023AmericasMarisa Woutersen

Cancer specialist to pay $83.4m over DNA sequencing infringement

TwinStrand Biosciences and the University of Washington win patent infringement case related to DNA mutation technology.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

Force pharma companies to provide drugs for rare cancer trials, UK govt told

30 January 2024 MHRA 'should regulate' the release of drugs for clinical trials for innovative cancer treatments | Medical experts lambast big pharma’s unacceptable lack of involvement in Glioblastoma campaign | Forcing companies will ‘undermine public trust’ says pharma body.

Guardant holds on to diagnostics patent following TwinStrand challenge

1 February 2024 PTAB says claims of genetic disease testing patent are not obvious | Rival biotech firm denied petition for invalidation.

More on this story

Guardant holds on to diagnostics patent following TwinStrand challenge

1 February 2024 PTAB says claims of genetic disease testing patent are not obvious | Rival biotech firm denied petition for invalidation.

Biotechnology

Force pharma companies to provide drugs for rare cancer trials, UK govt told

30 January 2024 MHRA 'should regulate' the release of drugs for clinical trials for innovative cancer treatments | Medical experts lambast big pharma’s unacceptable lack of involvement in Glioblastoma campaign | Forcing companies will ‘undermine public trust’ says pharma body.

More on this story

Guardant holds on to diagnostics patent following TwinStrand challenge

1 February 2024 PTAB says claims of genetic disease testing patent are not obvious | Rival biotech firm denied petition for invalidation.

Biotechnology

Force pharma companies to provide drugs for rare cancer trials, UK govt told

30 January 2024 MHRA 'should regulate' the release of drugs for clinical trials for innovative cancer treatments | Medical experts lambast big pharma’s unacceptable lack of involvement in Glioblastoma campaign | Forcing companies will ‘undermine public trust’ says pharma body.

More features

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent

‘We took Ravgen head-on’: How we won zero-damages and others didn't

Bristol Myers Squibb leader named INTA 2025 president

Kathi Vidal to leave USPTO ahead of incoming Trump administration

Herbert Smith Freehills and Kramer Levin in $2bn merger talks